Globus slapped with $1m FDA fine for selling "unapproved" NuBone; maintains it was a case of miscommunication
This article was originally published in Clinica
Executive Summary
Privately-held spinal company Globus Medical is to fork out $1m to settle allegations made by the US FDA that the firm continued to sell its NuBone bone graft product even though the agency had not approved it for sale.